861 RSV Hospitalization in Infants with Neuromuscular Disease in the Canadian Registry of Synagis® (Caress) Following Prophylaxis (2005–2011)

Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab use and respiratory outcomes in high-risk infants, including those with neuromuscular impairments (NMI). We compared respiratory illness (RI) and respiratory syncytial virus positive hospitalization (RSVH) rates in NMI...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2012-10, Vol.97 (Suppl 2), p.A247-A247
Main Authors: Paes, B, Li, A, Mitchell, I, Lanctot, KL
Format: Article
Language:English
Subjects:
Body Weight
Infants
Prophylaxis
Young Children
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A247
container_issue Suppl 2
container_start_page A247
container_title Archives of disease in childhood
container_volume 97
creator Paes, B
Li, A
Mitchell, I
Lanctot, KL
description Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab use and respiratory outcomes in high-risk infants, including those with neuromuscular impairments (NMI). We compared respiratory illness (RI) and respiratory syncytial virus positive hospitalization (RSVH) rates in NMI infants versus: 1) those with other underlying medical disorders (MD) and 2) those prophylaxed for standard indications (SD). Methods A prospective, observational registry of infants from 30 Canadian sites who received ≥1 dose of palivizumab during the 2005–2011 RSV seasons. Utilization and RI events were collected monthly throughout each season. Results 10452 infants were recruited (NMI: 118, 1.1%; MD: 1443, 13.8%; SD: 8891, 85.1%). There were statistically significant group differences (p5 individuals in the household, and history of atopy. NMI infants tended to have a less complex neonatal course. Compliance was similar across the three groups. The NMI group had higher RI hospitalization rates than MD or SD (17.8% versus 9.6% and 5.8%, p
doi_str_mv 10.1136/archdischild-2012-302724.0861
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1828861179</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4214772831</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2241-c94cacd6c41c43998762731a298f45d0ce105f7acb7e48175524df7fa08f9ee33</originalsourceid><addsrcrecordid>eNqVkcFu1DAQhiMEEkvhHSwhpPaQYjtO7Bw4oJTSolVZutCrNevYjZesvbUTtcuJR0DiPfoQfRSeBK-CEFdO1ljfP6OZL8teEXxMSFG9hqC61kbV2b7NKSY0LzDllB1jUZFH2YywSqR_xh5nM4xxkddCiKfZsxjXONFCFLPsR0LR5fIKnfm4tQP09hsM1jtkHTp3BtwQ0a0dOnShx-A3Y1RjDwGd2Kgh6j01dBo14KC14NClvrZxCDvkDVruHKTq4R4dNhB0jEfo1Pe9v7XuGi2C33a7Hu5sRIcU4_LX959pBXL0PHtioI_6xZ_3IPty-u5zc5bPP74_b97O8xWljOSqZgpUWylGFCvqWvCK8oIArYVhZYuVJrg0HNSKayYIL0vKWsMNYGFqrYviIHs59d0GfzPqOMi1H4NLIyUR6TYVIbxO1JuJUsHHGLSR22A3EHaSYLmXIP-VIPcS5CRB7iWkfD7l01X03d8whK-y4gUv5cVVI0-WHxbsUz2Xi8SLiV9t1v856jc5LqEE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1828861179</pqid></control><display><type>article</type><title>861 RSV Hospitalization in Infants with Neuromuscular Disease in the Canadian Registry of Synagis® (Caress) Following Prophylaxis (2005–2011)</title><source>Social Science Premium Collection</source><source>Education Collection</source><creator>Paes, B ; Li, A ; Mitchell, I ; Lanctot, KL</creator><creatorcontrib>Paes, B ; Li, A ; Mitchell, I ; Lanctot, KL</creatorcontrib><description>Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab use and respiratory outcomes in high-risk infants, including those with neuromuscular impairments (NMI). We compared respiratory illness (RI) and respiratory syncytial virus positive hospitalization (RSVH) rates in NMI infants versus: 1) those with other underlying medical disorders (MD) and 2) those prophylaxed for standard indications (SD). Methods A prospective, observational registry of infants from 30 Canadian sites who received ≥1 dose of palivizumab during the 2005–2011 RSV seasons. Utilization and RI events were collected monthly throughout each season. Results 10452 infants were recruited (NMI: 118, 1.1%; MD: 1443, 13.8%; SD: 8891, 85.1%). There were statistically significant group differences (p&lt;0.05) in: enrolment weight and age, gestational age, birth weight, proportions of: Caucasians, daycare attendance, smoking exposure, siblings, multiple birth, &gt;5 individuals in the household, and history of atopy. NMI infants tended to have a less complex neonatal course. Compliance was similar across the three groups. The NMI group had higher RI hospitalization rates than MD or SD (17.8% versus 9.6% and 5.8%, p&lt;0.0005), as well as RSVH (5.62% versus 1.98% and 1.49%, p&lt;0.0005). A Cox proportional hazard analysis showed that having NMI increased the risk of first RSVH compared to infants in the SD group (hazard ratio=4.47, 95% CI 1.96–10.18, p&lt;0.0005). Conclusions NMI infants comprise a very high risk cohort for RI and RSV-related hospitalization and should be considered for palivizumab prophylaxis to reduce incurred morbidities as recommended by the American Academy of Pediatrics and other international advisory bodies.</description><identifier>ISSN: 0003-9888</identifier><identifier>EISSN: 1468-2044</identifier><identifier>DOI: 10.1136/archdischild-2012-302724.0861</identifier><identifier>CODEN: ADCHAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</publisher><subject>Body Weight ; Infants ; Prophylaxis ; Young Children</subject><ispartof>Archives of disease in childhood, 2012-10, Vol.97 (Suppl 2), p.A247-A247</ispartof><rights>2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2012 (c) 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1828861179/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1828861179?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,21378,21394,27924,27925,33611,33877,43733,43880,74221,74397</link.rule.ids></links><search><creatorcontrib>Paes, B</creatorcontrib><creatorcontrib>Li, A</creatorcontrib><creatorcontrib>Mitchell, I</creatorcontrib><creatorcontrib>Lanctot, KL</creatorcontrib><title>861 RSV Hospitalization in Infants with Neuromuscular Disease in the Canadian Registry of Synagis® (Caress) Following Prophylaxis (2005–2011)</title><title>Archives of disease in childhood</title><addtitle>Arch Dis Child</addtitle><description>Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab use and respiratory outcomes in high-risk infants, including those with neuromuscular impairments (NMI). We compared respiratory illness (RI) and respiratory syncytial virus positive hospitalization (RSVH) rates in NMI infants versus: 1) those with other underlying medical disorders (MD) and 2) those prophylaxed for standard indications (SD). Methods A prospective, observational registry of infants from 30 Canadian sites who received ≥1 dose of palivizumab during the 2005–2011 RSV seasons. Utilization and RI events were collected monthly throughout each season. Results 10452 infants were recruited (NMI: 118, 1.1%; MD: 1443, 13.8%; SD: 8891, 85.1%). There were statistically significant group differences (p&lt;0.05) in: enrolment weight and age, gestational age, birth weight, proportions of: Caucasians, daycare attendance, smoking exposure, siblings, multiple birth, &gt;5 individuals in the household, and history of atopy. NMI infants tended to have a less complex neonatal course. Compliance was similar across the three groups. The NMI group had higher RI hospitalization rates than MD or SD (17.8% versus 9.6% and 5.8%, p&lt;0.0005), as well as RSVH (5.62% versus 1.98% and 1.49%, p&lt;0.0005). A Cox proportional hazard analysis showed that having NMI increased the risk of first RSVH compared to infants in the SD group (hazard ratio=4.47, 95% CI 1.96–10.18, p&lt;0.0005). Conclusions NMI infants comprise a very high risk cohort for RI and RSV-related hospitalization and should be considered for palivizumab prophylaxis to reduce incurred morbidities as recommended by the American Academy of Pediatrics and other international advisory bodies.</description><subject>Body Weight</subject><subject>Infants</subject><subject>Prophylaxis</subject><subject>Young Children</subject><issn>0003-9888</issn><issn>1468-2044</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>CJNVE</sourceid><sourceid>M0P</sourceid><recordid>eNqVkcFu1DAQhiMEEkvhHSwhpPaQYjtO7Bw4oJTSolVZutCrNevYjZesvbUTtcuJR0DiPfoQfRSeBK-CEFdO1ljfP6OZL8teEXxMSFG9hqC61kbV2b7NKSY0LzDllB1jUZFH2YywSqR_xh5nM4xxkddCiKfZsxjXONFCFLPsR0LR5fIKnfm4tQP09hsM1jtkHTp3BtwQ0a0dOnShx-A3Y1RjDwGd2Kgh6j01dBo14KC14NClvrZxCDvkDVruHKTq4R4dNhB0jEfo1Pe9v7XuGi2C33a7Hu5sRIcU4_LX959pBXL0PHtioI_6xZ_3IPty-u5zc5bPP74_b97O8xWljOSqZgpUWylGFCvqWvCK8oIArYVhZYuVJrg0HNSKayYIL0vKWsMNYGFqrYviIHs59d0GfzPqOMi1H4NLIyUR6TYVIbxO1JuJUsHHGLSR22A3EHaSYLmXIP-VIPcS5CRB7iWkfD7l01X03d8whK-y4gUv5cVVI0-WHxbsUz2Xi8SLiV9t1v856jc5LqEE</recordid><startdate>201210</startdate><enddate>201210</enddate><creator>Paes, B</creator><creator>Li, A</creator><creator>Mitchell, I</creator><creator>Lanctot, KL</creator><general>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88B</scope><scope>88E</scope><scope>88I</scope><scope>8A4</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>CJNVE</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0P</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEDU</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>201210</creationdate><title>861 RSV Hospitalization in Infants with Neuromuscular Disease in the Canadian Registry of Synagis® (Caress) Following Prophylaxis (2005–2011)</title><author>Paes, B ; Li, A ; Mitchell, I ; Lanctot, KL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2241-c94cacd6c41c43998762731a298f45d0ce105f7acb7e48175524df7fa08f9ee33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Body Weight</topic><topic>Infants</topic><topic>Prophylaxis</topic><topic>Young Children</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paes, B</creatorcontrib><creatorcontrib>Li, A</creatorcontrib><creatorcontrib>Mitchell, I</creatorcontrib><creatorcontrib>Lanctot, KL</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Education Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Education Periodicals</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Education Collection</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Education Database</collection><collection>Family Health Database (Proquest)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Education</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Archives of disease in childhood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paes, B</au><au>Li, A</au><au>Mitchell, I</au><au>Lanctot, KL</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>861 RSV Hospitalization in Infants with Neuromuscular Disease in the Canadian Registry of Synagis® (Caress) Following Prophylaxis (2005–2011)</atitle><jtitle>Archives of disease in childhood</jtitle><addtitle>Arch Dis Child</addtitle><date>2012-10</date><risdate>2012</risdate><volume>97</volume><issue>Suppl 2</issue><spage>A247</spage><epage>A247</epage><pages>A247-A247</pages><issn>0003-9888</issn><eissn>1468-2044</eissn><coden>ADCHAK</coden><abstract>Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab use and respiratory outcomes in high-risk infants, including those with neuromuscular impairments (NMI). We compared respiratory illness (RI) and respiratory syncytial virus positive hospitalization (RSVH) rates in NMI infants versus: 1) those with other underlying medical disorders (MD) and 2) those prophylaxed for standard indications (SD). Methods A prospective, observational registry of infants from 30 Canadian sites who received ≥1 dose of palivizumab during the 2005–2011 RSV seasons. Utilization and RI events were collected monthly throughout each season. Results 10452 infants were recruited (NMI: 118, 1.1%; MD: 1443, 13.8%; SD: 8891, 85.1%). There were statistically significant group differences (p&lt;0.05) in: enrolment weight and age, gestational age, birth weight, proportions of: Caucasians, daycare attendance, smoking exposure, siblings, multiple birth, &gt;5 individuals in the household, and history of atopy. NMI infants tended to have a less complex neonatal course. Compliance was similar across the three groups. The NMI group had higher RI hospitalization rates than MD or SD (17.8% versus 9.6% and 5.8%, p&lt;0.0005), as well as RSVH (5.62% versus 1.98% and 1.49%, p&lt;0.0005). A Cox proportional hazard analysis showed that having NMI increased the risk of first RSVH compared to infants in the SD group (hazard ratio=4.47, 95% CI 1.96–10.18, p&lt;0.0005). Conclusions NMI infants comprise a very high risk cohort for RI and RSV-related hospitalization and should be considered for palivizumab prophylaxis to reduce incurred morbidities as recommended by the American Academy of Pediatrics and other international advisory bodies.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</pub><doi>10.1136/archdischild-2012-302724.0861</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0003-9888
ispartof Archives of disease in childhood, 2012-10, Vol.97 (Suppl 2), p.A247-A247
issn 0003-9888
1468-2044
language eng
recordid cdi_proquest_journals_1828861179
source Social Science Premium Collection; Education Collection
subjects Body Weight
Infants
Prophylaxis
Young Children
title 861 RSV Hospitalization in Infants with Neuromuscular Disease in the Canadian Registry of Synagis® (Caress) Following Prophylaxis (2005–2011)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A59%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=861%20RSV%20Hospitalization%20in%20Infants%20with%20Neuromuscular%20Disease%20in%20the%20Canadian%20Registry%20of%20Synagis%C2%AE%20(Caress)%20Following%20Prophylaxis%20(2005%E2%80%932011)&rft.jtitle=Archives%20of%20disease%20in%20childhood&rft.au=Paes,%20B&rft.date=2012-10&rft.volume=97&rft.issue=Suppl%202&rft.spage=A247&rft.epage=A247&rft.pages=A247-A247&rft.issn=0003-9888&rft.eissn=1468-2044&rft.coden=ADCHAK&rft_id=info:doi/10.1136/archdischild-2012-302724.0861&rft_dat=%3Cproquest_cross%3E4214772831%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b2241-c94cacd6c41c43998762731a298f45d0ce105f7acb7e48175524df7fa08f9ee33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1828861179&rft_id=info:pmid/&rfr_iscdi=true